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Signs of Immaturity of Splenic Dendritic Cells from the
Autoimmune Prone Biobreeding Rat: Consequences for the
In Vitro Expansion of Regulator and Effector T Cells1
Frans G. A. Delemarre,2 Peter J. Simons, Hendrik Jan de Heer, and Hemmo A. Drexhage
From the biobreeding-diabetic prone (BB-DP) rat, an animal model for endocrine autoimmunity, phenotype and function of
splenic dendritic cells (DC) were studied. Furthermore, the suppressive effect of peritoneal macrophages (pMf) from the BB-DP
rat in the MLR was investigated. Lower numbers of splenic DC were isolated from BB-DP rats than from control Wistar rats. In
the preautoimmune phase, DC of the BB-DP rat had a lower surface MHC class II expression (and in preliminary data, a lower
CD80 expression), ingested more bacteria, and had a lower stimulatory potency in the syngeneic (syn)MLR as compared with
control DC. During disease development, the MHC class II expression further decreased, and a low stimulatory activity became
evident in the allogeneic (allo)MLR. With regard to the expansion of suppressor/regulatory T cells, a lower percentage of RT61
T cells but higher percentages of CD45RClow T cells were induced by BB-DP DC in synMLR, but not in alloMLR. An increase
in the CD4/CD8 T cell ratio was observed in both the syn- and alloMLR due to a relative weak expansion of CD81 T cells with
DC of the BB-DP rat. Resident pMf isolated from BB-DP or Wistar rats were equally effective in suppressing the DC-driven
synMLR. In conclusion, splenic DC from the BB-DP rat have a lower accessory cell function already at young age, before the
development of disease, and expanded different subsets of effector/suppressor T cells in vitro as compared with those from Wistar
rats. The dysfunction of DC from BB-DP rats is likely to be caused by their relative immaturity as indicated by their low class II
and costimulatory molecule expression and relatively high phagocytic activity. The Journal of Immunology, 1999, 162: 1795–
1801.
I n animal models that spontaneously develop endocrine auto-immune disease (EAD),3 such as the biobreeding-diabeticprone (BB-DP) rat and the nonobese diabetic (NOD) mouse,
the thyroid gland and pancreas are infiltrated by MHC class II1
dendritic cells (DC) in the preautoimmune phase (1–6). This initial
accumulation of DC is followed by an enlargement of the draining
lymph nodes and the production of autoantibodies by plasma cells
located in these lymph nodes (1, 3). In patients with type 1 diabetes
mellitus and autoimmune thyroid disease, DC also infiltrate the
target glands (1, 7–9).
The local accumulation of DC early in the development of dis-
ease suggests a pivotal role of these cells in the pathogenesis of
EAD. In patients with EAD, a defective maturation and function of
DC has been reported: in diabetic patients, there is a loss of MHC
class II1 Langerhans cells from the epidermis at the onset of di-
abetes (10) and a reduction in the number of DC generated from
monocytes, the precursor population in the peripheral blood (11).
These monocyte-derived DC had a low stimulatory capability in
autologous (auto)MLR (11), which was also described for unfrac-
tioned APC populations from the blood of diabetic patients (12–
15). Furthermore, monocyte-derived DC from patients with
Graves’ disease and from diabetic patients showed a reduction in
cellular interactions, i.e., the cells formed less homotypic clusters
and clusters with T cells as compared with DC from healthy
controls (11, 16).
A defective maturation and function of APC has also been
described in the NOD mouse. APC precursors in the bone mar-
row showed a weakened maturational response to the growth
factors IL-3 and CSF-1 (17), and splenic APC demonstrated a
low stimulatory capacity in the syngeneic (syn)MLR (18, 19).
Hence, these findings are—as in the human—indicative for a
maturational defect of APC underlying the poor stimulatory ca-
pability. Indeed, immature DC have been recognized as relative
poor T cell stimulators as compared with mature and activated
DC (20, 21). Apart from intrinsic maturational defects, a re-
duced function of APC can also be caused by an increased
production of suppressive factors from other monocyte-derived
cells, i.e., macrophages (Mf). Mf from NOD mice and BB rats
are able to produce high amounts of suppressive factors such as
prostaglandins and nitric oxide (22–29).
Optimal APC function is required for appropriate stimulation of
suppressor forces (12, 18). The reduced accessory cell function in
auto/synMLR was regarded, both in the NOD mouse and in the
patients, as a sign of a faulty capability to expand suppressor/
regulatory T cells. The advantage of studying the BB rat is the
presence of a well-defined suppressor/regulatory T cell population
expressing the Ag RT6. These T cells play an important regulatory
role in the pathogenesis of EAD in the BB-DP rat (30). BB-DP rats
lack RT61 T cells and injections of these cells into BB-DP rats
prevents EAD (31). BB-diabetic resistant (DR) rats do not develop
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diabetes and thyroid autoimmunity because of the presence of
RT61 T cells, but depletion of these cells induces EAD (32). Thus,
the BB rat is an excellent model to study putative functional de-
fects of DC in relation to a defective suppressor/regulatory T cell
expansion. We hypothesized that the loss of suppressor/regulatory
T cells in BB-DP rats, which is already evident at young age,
might be at least in part due to a defective function of DC before
the development of EAD. Therefore, the function of splenic DC
from BB-DP rats of different ages in allogeneic (allo)MLR (with
Lewis T cells) and synMLR (with Wistar and BB-DP T cells) was
studied. In particular, we were interested in BB-DP rats of ages
3–7 wk, i.e., before the DC infiltration into the thyroids and pan-
creas islets and before EAD development. We focussed on the in
vitro expansion of RT61 T cells within a normal T cell population
from Wistar and Lewis rats. Because CD81 cells and CD45RClow
cells have also been associated with regulatory T cells in the BB
rat (33, 34), CD4/CD8 ratios of the in vitro expanded T cells were
calculated and CD45RC expression was examined. DC of the
BB-DP rat proved to be less capable in generating RT61 and
CD81 T cells, and this could be due to an immature phenotype.
For this purpose, the uptake of dextran molecules and bacteria was
studied (20, 21), together with the expression of MHC class I and
II, costimulatory and adhesion molecules, the DC marker OX-62,
and the DC/Mf markers, ED1 and ED7. Finally, we studied the
ability of BB-DP Mf to reduce accessory cell function by adding




Male and female BB-DP rats were bred in the Experimental Animal Center
of the Erasmus University (Rotterdam, The Netherlands) and control
Wistar rats were purchased from Harlan (Zeist, The Netherlands). All rats
were kept under controlled light conditions (12/12 h light/dark cycle)
throughout this study. A standard pelleted diet (0.35 mg iodine/kg; AM-II,
Hope Farms BV, Woerden, The Netherlands) and tap water were provided
ad libitum. Between 12 and 20 wk of age, 90% of our BB-DP rats devel-
oped a-colloid Abs detected in serum, and 70–80% of the rats became
diabetic. BB-DP rats were daily tested for glucosuria (Gluketur test sticks;
Boehringer Mannheim BV, Almere, The Netherlands). For all experiments,
age matched BB and Wistar rats were used.
Cell preparations
Splenic DC were enriched according to the method of Knight et al. (35),
with slight modifications. Briefly, spleens from BB-DP and Wistar rats
were minced and digested for 1 h at 37°C in RPMI 1640 medium (Life
Technologies, Breda, The Netherlands) with 25 mM glutamax-1 and 25
mM HEPES (hereafter referred to as RPMI1) containing: 125 U/ml col-
lagenase (type III; Worthington Biochemical, Freehold, NJ) and 0.1 mg/ml
DNase (Boehringer Mannheim BV). The remaining tissue was teased
through a 105-mm filter, and the erythrocytes were removed by lysis. Fi-
nally, the separated cells were washed and cultured in RPMI1 supple-
mented with 10% inactivated FCS (FCSi), penicillin (100 U/ml; Seromed,
Biochrom, Berlin, Germany), and streptomycin (0.1 mg/ml; Seromed). Af-
ter an overnight culture period in culture flasks (Costar Europe, Badho-
evedorp, The Netherlands; 37°C, 5% CO2 incubator), DC were isolated
from the nonadherent cells by using a 14.5% (w/v) Nycodenz (Nycomed
Pharma As, Oslo, Norway) density gradient (800 3 g for 20 min). Low-
density cells were collected from the interphase and washed. This cell
fraction demonstrated a dendritic morphology, a strong MHC II expression
(see Results), and a weak acid phosphatase (AP) activity in 70–95% of
cells in both rat strains.
Resident pMf were harvested by lavage of the peritoneal cavity of
BB-DP and Wistar rats with 10 ml ice-cold PBS, pH 7.4, containing 50
U/ml heparin. Cells were washed, and, when present, erythrocytes were
lysed. The peritoneal fluid contained, in both rat strains, 50–63% ED21
and AP1 cells as determined on cytospin preparations.
T cells from BB-DP, Wistar, and Lewis rats were enriched using a nylon
wool column. In short, spleens were minced and teased through a 105-mm
filter, and the erythrocytes were removed by lysis. Cells were washed and
loaded onto a nylon wool column (3 g; Polyscience, Eppelheim, Germany)
packed into a 60 ml plastic syringe. After 1 h in 5% CO2 incubator, T cells
(80–90% CD51 cells) were harvested by collecting the effluent.
MLR
For the MLR, splenic DC from BB-DP and Wistar rats were irradiated with
2,000 rad and added at various ratios to T cells (fixed number of 150,000
T cells/well) in flat-bottom 96-wells plates (Nunc, Roskilde, Denmark).
Subsequently, these MLR were cultured for 3 or 5 days in RPMI 1640
containing 50 mM HEPES buffer (Life Technologies), 10% FCSi, 110
mg/ml sodium pyruvate (Merck, Munich, Germany), 0.5% (v/v) b-mer-
capto-ethanol (Merck), and antibiotics. To determine the effect of pMf on
accessory cell function, splenic Wistar DC were mixed with Wistar T cells
(150,000 T cells/well) at a ratio of 1:20, and pMf of either BB-DP or
Wistar rats were added at a DC:Mf ratio of 1:50, 1:10, and 1:2. As a
control, accessory cell function of the pMf alone were determined. Next,
cells were cultured for 5 days.
In the MLR, T cell proliferation was measured via tritiated thymidine
([3H]TdR) incorporation (0.5 mCi/well during the last 16 h of total culture
period). Finally, cells were harvested on filter papers, and radioactivity was
counted in a liquid scintillation analyzer (LKB Betaplate, Wallac, Turun,
Finland). For phenotyping (see below), T cells were collected and washed
in PBS containing 0.5% BSA (Sigma, Axel, The Netherlands) and 20 mM
sodium azide (Sigma).
Abs
The following mAbs were used: anti-MHC class I (1:400, MRC OX-18;
Serotec, Oxford, England), anti-MHC class II conjugated to phycoerythrin
(PE) (1:400; MRC OX-6, Serotec), anti-B7-1 (1:500, CD80; Research Di-
agnostics, Flanders, NJ), anti-B7-2 (1:500, CD86; Research Diagnostics),
anti-rat DC-PE (undiluted, MRC OX-62; Serotec) anti-LFA-1a (1:10,
CD11a; Serotec), anti-ICAM-1 (1:50, CD54; Serotec), anti-very late Ag-4
(VLA-4) (1:10, CD49b; Serotec), ED1 (1:400, monocytes, Mf), ED7 (1:
10, monocytes, Mf; both ED Abs were a kind gift from Prof. Dr. C. D.
Dijkstra, Department of Cell Biology, Free University, Amsterdam, The
Netherlands), anti-CD5 (1:100, MRC OX-19; Serotec) anti-CD4 conju-
gated to biotin (1:4, Domain 1; Serotec), anti-CD8-PE (1:4, MRC OX-8;
Serotec), anti-CD45RC (1:100, MRC OX-22; Serotec), anti RT6.1-FITC
(1:10, 3G2, for staining Lewis T cells), and anti-RT6.2-Biotin (1:10, GY
1/12, for staining Wistar T cells; both anti-RT6 Abs were a kind gift from
Dr. H. Groen, Department of Histology and Cell Biology, University of
Groningen, Groningen, The Netherlands).
Cell staining
Cells were added in round-bottom 96-wells plates (Nunc) at a concentra-
tion of ;105 cells/well and washed twice in PBS/0.5% BSA/20 mM so-
dium azide. Pelleted cells were resuspended in 20 ml solution with labeled
primary Abs, incubated for 10 min., and followed by two washing steps.
Using unconjugated Abs, a second step was incorporated with rabbit anti-
mouse-FITC Abs (Dako, Glustrup, Denmark) with 1% normal rat serum.
For the visualizing of biotin-conjugated Abs, streptavidin-tricolor (Caltac
Laboratories, San Francisco, CA) was used. For cell analysis, 10,000
events were recorded with a FACS (FACScan, Becton Dickinson, Sunny-
vale, CA). Dead cells, recognized by their uptake of propidium iodide and
their specific forward- and side-scatter pattern, were excluded from anal-
ysis. For determination of background staining, cells were incubated with
either labeled irrelevant Abs or with secondary Abs or with streptavidin-
tricolor alone.
Uptake of FITC-dextran
The uptake of FITC-dextran (Sigma) by DC was performed according to
the method by Sallusto et al. (20). In short, DC were added to round-bottom
96-wells plates (Nunc) at a concentration of 105 cells/well in RPMI1, 10%
FCSi, and antibiotics. FITC-dextran was added at a final concentration of
1 mg/ml for 0, 15, 30, and 60 min. After incubation, the cells were put on
ice and washed thrice. Finally, the cells were stained with OX-6-PE (Se-
rotec) and analyzed on a FACScan.
Phagocytosis of FITC-labeled Escherichia coli
For studying the uptake of E. coli bacteria by DC, a phagotest (Becton
Dickinson) was used according to the instructions of the manufacturer with
some minor modification. Briefly, 20 ml precooled E. coli bacteria were
added to suspension with DC (106 cells/ml in RPMI1, 10% FCSi, and
antibiotics). The controls remained on ice and the phagocytosis assay was
incubated for 309 and 609 at 37°C in an incubator under rotation (4 rpm).
Cells were put on ice, washed, and 100 ml quenching solution was added.
1796 DC DYSFUNCTION IN THE BB-DP RAT
Cells were washed thrice and stained with OX-6-PE (Serotec) and analyzed
on a FACScan.
Statistical analysis
The results are presented as means 6 SEM, and statistical analysis of the
data was performed with the Mann-Whitney U test.
Results
Number and phenotype of isolated DC
The percentages of isolated splenic DC from BB-DP rats were
significantly lower than from Wistar rats (1.0 6 0.7% vs 1.4 6
0.6%, p 5 0.003, n 5 6, age 3–20 wk). The purity of DC, relevant
for performing further functional studies (see below), was mea-
sured by dendritic morphology and MHC class II expression, and
did not differ for both rat strains (range 70–95%, data not shown).
In the preautoimmune phase, DC from BB-DP rats (age 3–7 wk)
demonstrated a lower surface MHC class II expression than those
from Wistar rats (mean fluorescence intensity (MFI) for Wistar
and BB-DP rats, respectively, was 1586 6 510 and 1084 6 386,
p 5 0.02, n 5 23). During development and expression of disease
(age 8–20 wk), surface MHC class II expression further decreased
on BB-DP DC (MFI for Wistar and BB-DP rats, respectively, was
1452 6 642 and 533 6 124, p 5 0.006, n 5 19; see also Fig. 1).
DC from both rat strains had a weak AP activity located in a spot
near the nucleus and did not differ in the percentage of positive
cells and expression of the following surface markers: MHC class
I molecules (MFI for Wistar and BB-DP rats, respectively, was
214 6 61 and 231 6 57, n 5 13); adhesion molecules LFA-1
(73 6 10 and 77 6 13, n 5 3), ICAM-1 (116 6 19 and 114 6 15,
n 5 4), and VLA-4 (65 6 6 and 61 6 11, n 5 3); DC/Mf markers
ED1 (57 6 14 vs 55 6 17, n 5 3) and ED7 (80 6 9 vs 72 6 9,
n 5 3). DC from both rat strains were negative for CD4 and CD8.
The rat DC marker OX-62 only showed a weak expression in our
hands on both Wistar DC and BB-DP DC (data not shown).
CD80 and CD86 expression was also determined, but in a lim-
ited series of experiments. DC from BB-DP rats (age 3–7 wk) had
a lower CD80 expression than those from Wistar rats (MFI for
Wistar and BB-DP rats, respectively, was 192 6 57 and 98 6 56,
n 5 3). The expression of CD86 did not differ for both rat strain
DC (214 6 76 and 224 6 82, n 5 3).
Uptake of dextran and E. coli bacteria
Incubation with FITC-dextran resulted in an increased uptake in
time by the DC and this tended to be higher for the BB-DP rat (age
3–20 wk) after 60 min. (MFI for Wistar and BB-DP rats, respec-
tively, was 67 6 9 and 81 6 14, n 5 6).
During incubation with FITC-E. coli bacteria, DC showed an
increased phagocytosis and after 60 min. significantly more bac-
teria were taken up by DC from the BB-DP rat (age 3–20 wk) as
compared with the Wistar rat (Table I). DC from BB-DP rats of
different ages (3–7 wk and 8–20 wk) did not differ in the uptake of
the bacteria (data not shown). In contrast with DC, .85% of
Wistar pMf, which are professional phagocytes, were loaded with
FITC-E. coli bacteria after 60 min (data not shown).
Proliferation of T cells
After 3 days in syn- and alloMLR, no differences in the prolifer-
ation of T cells were observed with DC from either BB-DP or
Wistar rats (data not shown). After 5 days, optimal proliferation
was observed, and in the synMLR with Wistar T cells a signifi-
cantly lower uptake of [3H]TdR by the T cells (low proliferation)
was found with DC from BB-DP rats compared with Wistar rats
for both age groups of 3–7 and 8–20 wk (Fig. 2). Similar results
were obtained in the synMLR with T cells from the BB-DP rat,
although the overall counts were much lower due to the reduced
proliferative capacity of these T cells (Fig. 2). Here, the number of
experiments were too low (n 5 2) to perform statistical analysis.
In the alloMLR, no differences in accessory cell function were
observed between DC from BB-DP and Wistar rats in the age
FIGURE 1. A histogram of MHC class II expression on splenic DC
from BB-DP and Wistar rats (age: 11 wk).
Table I. Percentage of MHC class II1 and FITC-E. coli1 splenic DC





Wistar 0.9 6 0.3 3.7 6 2.1 4.3 6 1.5a
BB 1.7 6 1.3 4.8 6 2.3 12.2 6 4.6
a p 5 0.03, Wistar vs BB-DP.
FIGURE 2. [3H]TdR uptake by T cells after 5 days of coculture with
splenic DC from BB-DP (f) and Wistar rats (M) (MLR with Wistar T
cells: n 5 6–7; p, p , 0.03 compared with Wistar for all DC: T cell ratios
used and for all age groups; MLR with BB T cells: n 5 2; MLR with Lewis
T cells: n 5 9–10; p, p , 0.03 compared with Wistar for all DC: T cell
ratios in age group 8–20 wk).
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group of 3–7 wk (Fig. 2). In contrast, BB-DP DC induced signif-
icantly less proliferation of Lewis T cells than Wistar DC in the
age group of 8–20 wk (Fig. 2). With DC isolated from lymph
nodes, similar results in the alloMLR for the different strains were
observed (data not shown).
Expansion of T cell subsets in DC-driven MLR
No differences in the expansion of T cell subsets were observed on
day 3 in the syn- and alloMLR (data not shown). On day 5 of these
MLR, a significant increase in the CD4/CD8 ratio with DC from
the BB-DP rat was observed (Table II). In the synMLR with T
cells from the BB-DP rat, similar observations were made: the
CD4/CD8 ratio with DC from Wistar and BB-DP rat was 0.7 6 0.2
and 2.1 6 0.5, respectively (n 5 2). In synMLR, significant lower
percentages of CD45RC1 and RT61 T cells were induced by
BB-DP DC as compared with Wistar DC. This was not observed
in the alloMLR using Lewis T cells (Table II). An example of
CD4, CD8, and RT6 expression on Wistar T cells cultured with
DC from Wistar and BB-DP rats is given in Fig. 3.
Effect of peritoneal macrophages in the synMLR
Different concentrations of pMf were cocultured with DC and T
cells from the Wistar rat to study their effect in the synMLR. Cul-
ture of DC together with T cells (DC:T cell ratio of 1:20) gave
.40,000 counts, whereas culture with pMf alone with T cells
resulted in a much lower T cell proliferation (Fig. 4). The addition
of pMf in the synMLR at a DC:Mf ratio of 1:50 and 1:10, re-
sulted in a similar inhibition of T cell proliferation for both rat
strains. No significant inhibitory effect on the DC-driven MLR was
found using lower numbers of pMf (DC:Mf ratio of 1:2; Fig. 4).
Discussion
DC form a heterogeneous population of bone marrow-derived cells
capable of providing immunizing and tolerizing signals for T cells.
Lymphoid DC, first described in the thymus, are able to restrict T
cell responses (36, 37). Myeloid DC induce T cell responses, both
of effector (38) as well as of regulator/suppressor forces (39–41),
and can be generated from CD141 monocytes (42). Monocyte-
derived myeloid DC are immature when residing in peripheral tis-
sues, but fully mature during traffic from the periphery to the lym-
phoid organs. Signals for maturation can be delivered by
monocytes (monokines), lymphocytes (cytokines, CD40 ligation),
and bacteria (LPS). Immature myeloid DC are characterized by a
relative high capability to take up foreign (antigenic) material,
whereas mature forms are better equipped to stimulate T cells (21).
This study demonstrates that splenic DC from the BB-DP rat
show signs of immaturity as indicated by the following. First, a
low expression of surface MHC class II molecules and also of
CD80 together with an enhanced uptake of bacteria is shown.
These abnormalities occurred already in the preautoimmune period
(3–7 wk of age) and, with respect to MHC class II expression,
further decreased in the autoimmune period (8–20 wk of age).
Although not analyzed in this study, determination of intracellular
class II expression would help to substantiate immaturity by dif-
ferences in the distribution of MHC class II molecules (20, 21).
Table II. Percentages of RT61 and CD45RC1 T cells and CD4/CD8 ratio after 5 days of coculture with
splenic DC from BB-DP and Wistar rats (n 5 6–13)
T cells
Percent RT61 Percent CD45RC1 CD4/CD8 Ratio
Wistar Lewis Wistar Lewis Wistar Lewis
Wistar DC 57.0 6 8.4a 48.9 6 2.9 47.0 6 5.2a 16.5 6 2.6 1.4 6 0.2a 1.3 6 0.1a
BB DC 43.6 6 7.4 43.0 6 3.2 33.2 6 4.7 15.2 6 2.1 3.5 6 0.4 2.0 6 0.3
a p , 0.02, Wistar vs BB-DP.
FIGURE 3. Expression of CD4, CD8 (in a dotplot), and RT6 (fluores-
cence combined with forward scatter) on Wistar T cells after 5 days of
coculture with splenic DC from BB-DP or Wistar rats in the synMLR.
FIGURE 4. [3H]TdR uptake by Wistar T cells after 5 days of coculture
with splenic Wistar DC and/or pMf from BB-DP and Wistar rats (n 5
7–11; p, p , 0.01 for differences in T cell proliferation by Wistar DC as
compared with pMf alone or DC combined with pMf at a ratio of 1:50
and 1:10 for both rat strains).
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Second, a lower T cell stimulatory capacity in the synMLR for all
periods studied, and also in the alloMLR in the autoimmune period
is shown.
In addition, BB-DP splenic DC were also less in number upon
isolation, which may be taken as a sign for a reduced generation/
maturation of DC from their precursors. Further studies with
monocyte-derived and bone marrow-derived DC and the effect of
maturation stimuli like LPS are planned, as these would best an-
swer the issues regarding defective DC maturation and function in
the BB-DP rat.
The described DC dysfunction before the onset of autoimmu-
nity, i.e., before the accumulation of DC in the thyroids and pan-
creas islets of the BB-DP rat, is suggestive for an innate defect,
which may form the basis for the development of EAD and ag-
gravates during aging/disease. Interestingly, similar impaired func-
tion of DC has recently been described in the preclinical phase of
human diabetes (43).
How do our findings relate to other studies on DC and APC
function in the BB-DP rat? In a similar study, but using another
subline of BB-DP rats, Tafuri et al. (44) reported the same level of
MHC class II expression and accessory cell activity of splenic DC
from BB-DP and Wistar rats. However, these authors only studied
young rats (age 3–7 wk) and tested their DC in alloMLR but not
in synMLR. Also, we could not demonstrate DC defects in al-
loMLR at such young age. In other studies, using nonpurified APC
populations (45, 46), the data are sometimes confusing, and com-
parison with our data is difficult. In contrast with our findings,
Bellgrau et al. (45) reported, using unfractioned lymph node cells,
a normal synMLR, although these APC induced a lower response
in the alloMLR. It is not clear from their report whether experi-
ments were performed with either young or old rats. Also Elder et
al. (46) described that alloMLR driven by unseparated BB-DP
spleen cells was lower, as compared with those driven by Wistar
rat APC. But, higher T cell stimulations with BB-DP DC could be
obtained depending on the conditions of the experiment and the
concentration of the stimulator cells (46). In addition, it must be
noted that the unfractioned APC populations used in the above-
cited studies may contain Mf, which are likely to affect the pro-
liferation of the responder T cell population (see present data and
Refs. 22, 23, and 28).
Both in diabetic patients and in NOD mice, the failure of DC to
sufficiently stimulate T cells in auto/synMLR has been considered
as reflecting a decreased capability of these cells to expand regu-
latory/suppressor T cells (12, 18). Indeed, in the present study, the
reduced accessory cell function of the immature splenic DC from
the BB-DP rat resulted in the following conditions. First, a low
generation of RT61 T cells in synMLR is found. The RT61 pop-
ulation has been reported to contain cells that protect BB rats
against the development of EAD (31, 47). RT6 is a glycosyl-phos-
phatidylinositol-linked surface molecule present on ;70% of ma-
ture peripheral T cells (48, 49). The exact mechanism of protection
is not clear but the RT6 molecule generates an activation signal,
which may influence T cell function (50). Second, an increased
CD4/CD8 ratio, due to a primary expansion of CD41 T cells, not
only in synMLR (when BB-DP T cells or Wistar T cells were used
as responder cells), but also in allogeneic responses (Lewis T
cells), is found.
Taken together our data showing a low in vitro expansion of
RT61 T cells and of CD81 T cells (in relation to CD41 T cells)
by immature BB-DP splenic DC supports our hypothesis that DC
with a defective T cell stimulatory function, which can also be
found in human type 1 diabetes, have an inability to generate suf-
ficient suppressor forces (see Introduction). However, some words
of caution are necessary.
First, in our experiments with BB-DP DC, we have not made a
comparison with splenic DC and/or T cells of BB-DR rats to link
the maturation defect of DC to EAD development and to avoid
minor histocompatability differences in synMLR. A DR variant of
our BB-DP Rotterdam strain does not exist, but in a few prelim-
inary experiments we compared accessory cell function of splenic
DC of BB-DP and BB-DR rats of the Worcester strain. Interest-
ingly, DC of both Worcester strains did not show the defects as
observed with DC of the Rotterdam strain. In this respect, it is of
note that our BB-DP strain has a relatively high prevalence of
thyroiditis (51, 52). We did find other signs of immaturity of DC
from the Worcester sublines: a lower homotypic cluster capability
as compared with the Wistar rat, and the BB-DP rat was more
affected than the BB-DR rat. At present, these data are subject for
further study.
Second, suppressor activity has not only been recognized in the
RT61 and CD81 T cell population, but also in a population of
CD45RClow T cells (33, 47), and, within the CD41 T cells, these
cells have been recognized as Th2-like cells, producing IL-4 (33).
In our study, DC from the BB-DP rat induced not less, but more of
these “suppressor” CD45RClow T cells in vitro as compared with
the Wistar rat. Furthermore, the CD45RChigh/CD45RClow ratios of
both CD41 and CD81 T cell subsets did not differ in the MLR for
both rat strains using either Wistar or Lewis T cells (data not
shown). On the other hand, not only CD45RClow T cells may act
as suppressor/regulatory cells; also CD41 CD45RChigh Th1-like
cells can act as regulator cells suppressing graft rejection in the
Lewis rat (53). Hence, protective cell populations other than
CD81, RT61, or CD45RClow T cells are likely present in the
BB-DP rat. In addition, transplantation of thymic tissue from DR
rats into BB-DP rats prevented the development of diabetes with-
out restoration of the RT61 T cell population (54). Nagata et al.
(55) reported the prevention of diabetes in BB-DP rats with a
CD41CD82 and RT62 T cell line, but it is not clear whether this
cell line may obtain the RT6 phenotype after transfer. The present
studied showed that DC from the BB-DP rat expanded different
subsets of effector and suppressor/regulatory T cell populations in
vitro as compared with Wistar control rats. The question remains
whether BB-DP DC are indeed less capable of expanding T cells
that suppress EAD in vivo. This question may be solved by study-
ing the effect of in vitro expanded T cells (in synMLR) on the
development of EAD after transfer in BB-DP rats.
The mechanisms of the defective maturation of splenic DC from
the BB-DP rat could hypothetically reside on the level of the pre-
cursor in the bone marrow, as observed for NOD APC (17), or on
other levels, such as a lack of maturation signals. The latter is
illustrated by the transition from blood monocyte to full mature
DC induced by lymphocyte-derived cytokines and lymphocytic
contacts (CD40 ligation). Already at young age, the BB-DP rat
becomes severely lymphopenic (46, 56, 57), resulting in a strong
reduction in the number of especially CD81, CD45RC1, and
RT61 T cells (58–60). This reduction is at least partly due to
genetically encoded defects in intrathymic T cell maturation (60–
62). Hence, the T lymphopenia of the BB-DP rat could be primary
and induce a faulty cross-talk between lymphocytes and DC lead-
ing to a poor development and maturation of both T cells and DC.
The observation that DC from BB-DP rats (age 3–7 wk) stimulated
the alloMLR equivalently to Wistar DC (see Fig. 2), suggests that
the maturation and function of BB-DP DC can be restored with
“normal” T cells. Indeed, preliminary data showed a restoration of
homotypic cluster formation of BB-DP DC after incubation with
factors produced by Con A-stimulated T cells. Whether MHC class
II and CD80 expression is also restored is now under investigation.
We favor the idea that the defective cross-talk between DC and T
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cells of the BB-DP rat resides on both the intra- and extrathymic
level. Extrathymic defects in T cell maturation in the BB-DP rat
have been suggested before. With respect to the defective intra-
thymic T cell maturation in the BB-DP rat, a role for thymic APC
has also been recognized: introduction of a bone marrow-derived
thymic APC fraction from DR donors into the thymus of the
BB-DP rat restored the T cell proliferative function and prevented
disease. However, no restoration of the T lymphopenia and RT6
expression was achieved (54).
Mf-derived factors may also play a role in the defective DC
maturation in BB-DP rats. One of the major maturation-inducing
cytokines for DC, TNF-a (21, 63, 64), is produced in much lower
quantities by pMf of BB-DP rats than by BB-DR rats (65). Treat-
ment with or induction of TNF-a with CFA decreased the inci-
dence of diabetes in the BB-DP rat (66, 67). One could speculate
whether such treatment would induce a full maturation of BB-DP
DC and subsequently up-regulate their accessory cell function in
MLR. However, preliminary data showed that culture of splenic
BB-DP DC in the presence of a single dose of rat or human TNF-a
and/or combined with another maturation-inducing cytokine hu-
man granulocyte-Mf CSF, had no effect on their accessory cell
function in the MLR (data not shown).
Defective function of BB-DP splenic DC could also be due to an
excessive production of suppressive factors by BB-DP Mf, but
pMf of BB-DP and Wistar rats had similar inhibitory activities on
the synMLR driven by splenic DC of Wistar rats. These data are
in contrast to some previous reports demonstrating a stronger sup-
pression of APC by Mf of the BB-DP rat and an enhanced pro-
duction of suppressive factors (22, 23, 27, 28). However, other
data show the opposite: the addition of BB-DP Mf enhanced the
stimulatory activity of DC (44). These conflicting data may be due
to the usage of different populations of Mf (either isolated from
the spleen or the peritoneum) and differences in the activation state
of these Mf (e.g., exudate vs resident pMf, the latter being
strongly affected by the isolation procedure). In our study, cells
were harvested from the peritoneum without further purification
steps, like adherence or gradient centrifugation (22, 23, 27, 28),
ensuring a minimal degree of activation. If indeed BB-DP Mf
have a stronger suppressive effect (22, 23, 27, 28), this would
further limit the already depressed BB-DP DC activity.
In conclusion, the present study gives evidence that splenic DC
from the BB-DP rat have an immature phenotype and an impaired
function before the development of endocrine autoimmunity. Fur-
thermore, these defective DC induce a different expansion of T cell
subsets in vitro and the question remains whether these APC de-
fects also lead to a faulty in vivo induction of tolerance/suppres-
sion. The putative mechanisms underlying this altered maturation
(defective bone marrow factors, T cell defects) remain to be
elucidated.
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